The two-part, open-label, dose escalation phase I clinical study is designed to evaluate VX-680 when administered over a five-day treatment cycle in patients with hematologic cancers.
The study will evaluate VX-680 in patients with relapsed or refractory acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), acute lymphocytic leukemia (ALL) or chronic myelogenous leukemia (CML) in blast crisis. With the start of this clinical study, Merck and Vertex now have three clinical studies underway with VX-680 in cancer.
The initiation of this clinical study is supported by VX-680’s activity against hematologic cancers in both in vitro and in vivo studies. VX-680 is a potent inhibitor of Aurora kinases and of Flt-3 kinase, which have been implicated in the onset and progression of human leukemias. VX-680 has demonstrated prolonged survival and induced sustained remission in a model of human AML, and has also shown profound effects in a number of other preclinical cancer models.
“The biologic profile and preclinical studies of VX-680 indicate that this compound has the potential for treating a broad range of human leukemias by inducing apoptosis in the cells that drive disease,” said Dr Stephen Friend, executive vice president, Advanced Technology and Oncology, Merck Research Laboratories.